Bayer's Legal and Financial Gauntlet Reaches Critical Juncture

Bayer holds 2026 guidance as Supreme Court glyphosate hearing and shareholder meeting approach. Key decisions on liability, board, and dividend set to shape future.

Investors in Bayer AG are navigating a complex landscape where a significant legal milestone and a key shareholder meeting are set to unfold within days of each other. The German conglomerate enters this pivotal period holding firm to its financial guidance for 2026, even as it braces for a Supreme Court hearing that could reshape its future liability.

The company’s US pharmaceutical chief, Sebastian Guth, has stated that newly proposed US tariffs on imported brand-name drugs do not necessitate a change to the annual forecast. Guth cited the US commitment to uphold its trade agreement with the EU, which caps duties on most goods, including medicines, at 15 percent. While sixteen major global drugmakers have reportedly signed preliminary exemption deals, Guth did not confirm whether Bayer is now engaged in similar negotiations. The company's targets remain unchanged: it aims for adjusted EBITDA of 9.6 to 10.1 billion euros and currency-adjusted sales of 45 to 47 billion euros this year.

All eyes, however, are shifting to Washington D.C. Oral arguments before the US Supreme Court are scheduled to begin on April 27. Bayer’s case hinges on the argument that federal pesticide law (FIFRA) preempts state-level cancer warning requirements for its glyphosate-based herbicide. A favorable ruling would undermine the legal foundation for thousands of future lawsuits alleging the weedkiller causes non-Hodgkin’s lymphoma. The financial stakes are immense, with provisions for ongoing litigation standing at 11.8 billion euros, the majority related to glyphosate.

The outcome is critical for Bayer's cash position. Management anticipates litigation-related outflows of approximately five billion euros in 2026 alone, pushing the projected free cash flow deeply negative. This pressure persists despite progress on debt reduction; net financial debt declined to about 29.8 billion euros at the end of 2025, an 8.5 percent drop year-over-year. In a separate positive development, Kentucky recently became the third US state to enact a law shielding Bayer from certain glyphosate claims, following North Dakota and Georgia.

Shareholders will convene virtually for the Annual Stockholders' Meeting on April 24. The agenda includes the election of new supervisory board members—Marcel Smits and Alfred Stern are slated to replace Paul Achleitner and Colleen Goggins—and a vote on a dividend of 0.11 euros per share for fiscal 2025. The gathering offers a first glimpse of investor sentiment regarding the dual challenges of debt management and persistent legal risk.

The calendar remains crowded following these April events. The company will report quarterly figures on May 12, which are expected to include initial management commentary on the Supreme Court hearing. Furthermore, a critical deadline looms on June 4, by which plaintiffs must opt out of a nationwide class settlement announced in February. Bayer has reserved the right to terminate that settlement agreement if participation is deemed insufficient. The Supreme Court's final ruling, expected by summer, will ultimately determine if the company can permanently cap its largest source of legal expense.